NADH vs NMNH: Stability, Bioavailability & the Dosage-Form Decision

A plain-language guide to the two reduced NAD⁺ coenzymes — why they are the hardest precursors to stabilize, and how enteric coating, liposomal delivery, and supplier purity control decide whether they actually survive to do their job.

Why the Reduced Coenzymes Are the Hard Ones

Every NAD⁺ precursor has a stability problem, but the oxidized forms — NMN and NAD⁺ — are comparatively forgiving. Add two extra hydrogen atoms to reduce the nicotinamide ring, and the molecule becomes eager to give those electrons back. NADH and NMNH oxidize in contact with oxygen, degrade in light, and break down fastest in the acidic, enzyme-rich environment of the stomach.

This is not a footnote; it is the entire commercial problem. A reduced coenzyme that reaches the small intestine intact is a premium ingredient. One that oxidized in the capsule is just an expensive placebo. That is why, for these two molecules more than any others in the category, the dosage form and the purity control are the product — the chemistry only gets you so far.

NADH: The Energy-Loaded Electron Donor

Nicotinamide adenine dinucleotide (reduced), or NADH (CAS 606-68-8), is the reduced form of NAD⁺. It is the direct electron donor at Complex I of the mitochondrial electron transport chain — the molecule that hands off the high-energy electrons that ultimately drive ATP synthesis in every aerobic cell. If NAD⁺ is the coenzyme’s “empty” state, NADH is the “charged” state, loaded with reducing power.

That reducing power is exactly what makes it fragile. Analytical studies show NADH degrades measurably in solution within minutes to hours, with degradation accelerating in acidic conditions and at higher temperature — a classic Anal Biochem study using UV-visible spectrophotometry and factorial design found that pH, temperature, and buffer type all significantly affect NADH oxidation rates, with the best stability achieved in alkaline media at low temperature (Rover Júnior et al., Analytical Biochemistry, 1998 — PubMed). More recent long-term stability work confirms the same chemistry: NADH undergoes acid-catalyzed degradation at low pH, and the optimal pH for minimizing degradation of the reduced form is around 8.5 (Long-Term Stability of Nicotinamide Cofactors in Common Aqueous Buffers, Molecules, 2024 — PubMed Central). For oral supplementation, the practical consequence is that plain NADH powder in a standard gelatin capsule is a poor gamble unless the finished form protects it from stomach acid and oxidation — oxygen-driven degradation of the reduced ring has been mechanistically documented since the 1980s (Bernofsky & Wanda, Journal of Biological Chemistry, 1982 — PubMed).

NMNH: The Reduced NMN with a Potency Story

Dihydronicotinamide mononucleotide, or NMNH (CAS 108347-85-9), is the reduced form of NMN — the same β-nicotinamide mononucleotide scaffold with a hydrogen-rich nicotinamide ring. Our existing explainer on NMNH covers how it sits on the same NAD⁺ biosynthetic pathway as NMN. Here the relevant point is narrower: NMNH shares NMN’s delivery logic but adds the same electron-donating instability as NADH.

Because NMNH is promoted as a high-potency alternative to NMN — with claims of faster or stronger NAD⁺ elevation — buyers often overlook that its shelf and gut stability is the binding constraint on those claims. A reduced NMN that degrades before absorption delivers no more than ordinary NMN, and possibly less. The potency story is only real if the reduced state survives manufacture, storage, and the stomach — and the same acid-catalyzed degradation chemistry documented for NADH (Molecules, 2024) applies to its reduced nicotinamide ring.

NADH vs. NMNH: A Direct Comparison

Both are supplied by MAINTAIN Biotech as high-purity bulk powder with enzymatic synthesis; the difference that matters to a formulator is the delivery route, not the molecular claim.

The Dosage Form Is the Real Decision

For the reduced coenzymes, the raw ingredient and the finished dosage form cannot be separated. Three approaches dominate, and they solve different parts of the problem:

Enteric coating — solving the stomach

The stomach’s pH of roughly 1.5 to 3.5 is hostile to NADH and NMNH — precisely the acid-catalyzed degradation regime documented in the cofactor stability literature (Molecules, 2024). An enteric coating that resists gastric acid and dissolves only in the higher-pH small intestine protects the molecule through the most dangerous stretch of the journey. This is the most established, cost-effective protection strategy and is the reason our NADH and NMNH products are positioned for pellet and enteric formulations rather than loose powder in a capsule.

Liposomal delivery — adding a barrier and a carrier

Encapsulating the coenzyme in a phospholipid bilayer adds a physical barrier against oxygen and acid and may improve cellular uptake by mimicking the body’s own membranes. Liposomal NAD⁺ precursors have become a recognizable premium category, and the same logic applies to the reduced forms. The trade-off is cost and manufacturing complexity, which is why liposomal delivery is usually reserved for higher-margin finished products.

Antioxidant and dry-state engineering

Even before the dosage form, the bulk powder itself can be stabilized: low-moisture drying, oxygen-barrier packaging, desiccant control, and co-formulation with antioxidants such as ascorbic acid or vitamin E. A supplier that controls residual moisture and oxidation at the powder stage gives the formulator a much wider safety margin downstream.

What to Verify Before You Buy Bulk Powder

When you source NADH or NMNH as a raw material, four checks separate a supply chain you can build a brand on from one that will fail a stability test:

• Purity and the reduced-form assay. Confirm the specification quotes purity on the reduced molecule (≥99.8% is the bar we hold), not on a mixed pool that includes oxidized product.
• Synthesis route. Green enzymatic synthesis avoids the harsh reducing agents used in some chemical routes, leaving a cleaner impurity profile — a real advantage for a molecule this sensitive.
• Residual moisture and packaging. Ask for loss-on-drying data and confirm oxygen-barrier packaging with desiccant; these directly predict shelf life.
• Stability data under your conditions. Request accelerated stability data (e.g., 40°C/75% RH) and a specification for the oxidized impurity limit over time.

For the full picture of how these molecules fit the broader NAD⁺ landscape, our comparison of NAD⁺ precursors and our research & applications overview are useful next reads.

Frequently Asked Questions

Conclusion

NADH and NMNH are the most potent and the most fragile members of the NAD⁺ precursor family. Their commercial value depends less on the molecule and more on two decisions made downstream: how the finished dosage form protects them, and how the supplier controls purity and oxidation at the powder stage.